Shanghai ST-segment Elevation Myocardial Infarction Cohort

ST Elevation Myocardial Infarction Clinical Trial

Official title:

A Prospective Multicentre Cohort Study of Acute ST-segment Elevation Myocardial Infarction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05450757
• Other study ID #: RJH-STEMI
• Status: Recruiting
• Start date: September 12, 2018
• Est. completion date: September 17, 2024

Study information

• Verified date: July 2022
• Source: Ruijin Hospital
• Contact: Shuo Feng, M.D.,Ph.D.
• Phone: +86 15921388296
• Email: fengshuorv[@]hotmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

ST-segment elevation myocardial infarction(STEMI) remains a major cause of morbidity and mortality worldwide, despite of the early reperfusion therapy, including fibrinolysis, primary percutaneous coronary intervention (PCI),and standardized medical treatment.To improve the prognosis of STEMI patients, the management in their hospitalization should be optimized, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through PCI (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as lipid-lowering therapy.

This study aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Description:

This study is a prospective cohort study. It aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: September 17, 2024
• Est. primary completion date: September 17, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• ST elevation myocardial infarction

• Coronary angiography and percutaneous coronary intervention within 12 hours of symptom onset

• Capable and willing to provide informed conset and capable of completing study visits

Exclusion Criteria:

• Cardiovascular shock at admission

• Severe physical disability

• Active malignant tumors

• Active autoimmune diseases

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• ST Elevation Myocardial Infarction

Locations

Country	Name	City	State
China	Ruijin hospital, Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	Shanghai Fengxian District Central Hospital	Shanghai	Shanghai
China	Shanghai Fifth People's Hospital, Fudan University	Shanghai	Shanghai
China	Shanghai Jiading District Central Hospital	Shanghai	Shanghai
China	Shanghai Minhang District Central Hospital	Shanghai	Shanghai
China	Shanghai Putuo District Central Hospital	Shanghai	Shanghai
China	Shanghai Yangpu District Central Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Synchronized analysis of phonocardiogram and electrocardiogram	Synchronized PCG and ECG data using a wearable cardiac monitoring patch	1 day, 1 month, 6 months, 1 year
Primary	MACE	Major adverse cardiovascular events(MACE) in one year follow-up	0-1 year
Primary	Left Ventricular Function	Left ventricular end diastolic volume(LVEDV),Left ventricular end systolic volume(LVESE),Left ventricular ejection fraction(LVEF) changes within one year follow-up	1 month, 6month and 1 year
Primary	Coronary angiography	The pathological changes in culprit vessels in 1 year	1 year